In 2003, an international working group last reported on recommendations for diagnosis,
response assessment, and treatment outcomes in acute myeloid leukemia (AML). Since that …

Context The optimal treatment of acute myeloid leukemia (AML) in first complete remission
(CR1) is uncertain. Current consensus, based on cytogenetic risk, recommends …

Molecular analyses of leukemic blasts from patients with acute myeloid leukemia (AML)
have revealed a striking heterogeneity with regard to the presence of acquired gene …

Despite major improvements in outcome over the past decades, acute myeloid leukemia
(AML) remains a life-threatening malignancy in children, with current survival rates of∼ …

The homeobox (HOX) genes are a highly conserved family of homeodomain-containing
transcription factors that specify cell identity in early development and, subsequently, in a …

Purpose Patients with acute myeloid leukemia (AML) and FLT3/internal tandem duplication
(FLT3/ITD) have poor prognosis if treated with chemotherapy only. Whether this alteration …

Purpose To evaluate frequency, biologic features, and clinical relevance of RUNX1
mutations in acute myeloid leukemia (AML). Patients and Methods Diagnostic samples from …

Purpose The tet oncogene family member 2 (TET2) gene was recently identified to be
mutated in myeloid disorders including acute myeloid leukemia (AML). To date, there is …

The molecular analysis of biomarkers in oncology is rapidly advancing, but the incorporation
of new molecular tests into clinical practice will require a greater understanding of the …

Purpose We assessed the prognostic impact of IDH1 R132 mutations and a known single
nucleotide polymorphism (SNP) located in the same exon of the IDH1 gene in patients with …